AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15276394
Drug: Darusentan 25
RxNorm normalized name: Darusentan
DrugBank: Darusentan (DB04883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darusentan 25 mg
Trial: 19748665
Drug: Darusentan 50
RxNorm normalized name: Darusentan
DrugBank: Darusentan (DB04883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darusentan 50 mg
Trial: 26412349
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy alone without chemotherapy (for recurrence score of 0 to 10)
Trial: 23679351
Drug: Motesanib 125
RxNorm normalized name: Motesanib
DrugBank: Motesanib (DB05575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motesanib 125 mg once daily (Arm A)
Trial: 23679351
Drug: Motesanib 75
RxNorm normalized name: Motesanib
DrugBank: Motesanib (DB05575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motesanib 75 mg twice daily, 14-days-on/7-days-off (Arm B)
Trial: 23679351
Drug: Motesanib 75
RxNorm normalized name: Motesanib
DrugBank: Motesanib (DB05575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motesanib 75 mg twice daily, 5-days-on/2-days-off (Arm C)
Trial: 19180923
Drug: vecuronium bromide
RxNorm normalized name: Vecuronium Bromide
DrugBank: Vecuronium (DB01339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vecuronium bromide 0.1 mg/kg (control group)
Trial: 16635694
Drug: Levalbuterol (Lev)
DrugBank: Levosalbutamol (DB13139)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levalbuterol (Lev) 1.25 mg
Trial: 16635694
Drug: Racemic albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic albuterol (Rac) 2.5 mg
Trial: 16635694
Drug: Racemic albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic albuterol (Rac)
Trial: 8973725
Drug: anti-H2 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-H2 treatment
Trial: 19559376
Drug: Emergency treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency treatment for renal colic
Trial: 12088118
Drug: Droloxifene 40
RxNorm normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene 40 mg/d
Trial: 2127424
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion x 5 days recombinant gamma-interferon
Trial: 31557693
Drug: Mindfulness-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive Therapy (MBCT) + Treatment As Usual (TAU)
Trial: 25573533
Drug: Gemcitabine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine alone (1000 mg/m(2))
Trial: 18046223
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) 1.25 mg and intravitreal triamcinolone (IVT) 2 mg
Trial: 17550489
Drug: Menevit antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menevit antioxidant (one capsule per day for three months)
Trial: 17550489
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical in appearance to Menevit, one capsule per day for three months)
Trial: 24149401
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - no treatment
Trial: 11598393
Drug: Oral folate
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral folate (5 mg/day)
Trial: 9688014
Drug: Intermittent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent therapy at the time of symptomatic relapses
Trial: 9688014
Drug: Fluconazole (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (up to 800 mg/day)
Trial: 7805084
Drug: More potent
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More potent and specific antithrombin and antiplatelet agents
Trial: 338851
Drug: Hydrochlorothiazide (HCT)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT) and Spironolactone (SP) in combination
Trial: 25847900
Drug: cinacalcet in
RxNorm normalized name: Product containing cinacalcet in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cinacalcet in combination with potassium citrate and allopurinol
Trial: 23556995
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy only (Control group)
Trial: 21410125
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia (150 mL of 300 mg ropivacaine, 30 mg ketorolac, and 500 μg epinephrine) with an additional 100 mg ropivacaine on postoperative day 1.
Trial: 21410125
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with a single‐shot femoral nerve block (150 mg of ropivacaine with epinephrine).
Trial: 16902175
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy on music (same amount as whole-body vibration)
Trial: 12782920
Drug: Ganstigmine 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganstigmine 12.5 mg
Trial: 12782920
Drug: Ganstigmine 10
RxNorm normalized name: Ganstigmine
DrugBank: Ganstigmine (DB06525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganstigmine 10 mg
Trial: 12782920
Drug: Ganstigmine (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganstigmine (5, 7.5, 10 mg)
Trial: 12782920
Drug: Ganstigmine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganstigmine (all doses)
Trial: 11048830
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (60 mg daily from 24 weeks' gestation through delivery)
Trial: 11048830
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (60 mg daily from 24 weeks' gestation through delivery) and Placebo
Trial: 9091506
Drug: 0.05% tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% tretinoin emollient cream (Renova, Retinova)
Trial: 9091506
Drug: 0.05% tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% tretinoin emollient cream (Renova, Retinova) continued for another 6 months
Trial: 2279256
Drug: Ibopamine 200
RxNorm normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine 200 mg b.i.d.
Trial: 8225657
Drug: Furosemide 40
RxNorm normalized name: furosemide 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 40 mg q.d.
Trial: 3703495
Drug: Intravitreal thrombin
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal thrombin (100 units/ml)
Trial: 20169667
Drug: Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel plus carboplatin (TC) therapy: 180 mg/m2 paclitaxel on day 1 plus AUC 6 mg/mL x minute carboplatin on day 1 every 21 days
Trial: 20169667
Drug: Irinotecan plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan plus cisplatin (CPT-P) therapy: 60 mg/m2 irinotecan hydrochloride on days 1, 8, 15 plus 60 mg/m2 cisplatin on day 1 every 28 days
Trial: 7527108
Drug: Nifedipine slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine slow-release (SR) 20 mg twice daily
Trial: 7527108
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of trandolapril and nifedipine SR
Trial: 26412801
Drug: Higher-bioavailability BNX
RxNorm normalized name: BNX
DrugBank: Oxybuprocaine (DB00892)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher-bioavailability BNX sublingual tablet
Trial: 19556972
Drug: Aliskiren combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren combination therapy
Trial: 19556972
Drug: Aliskiren monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren monotherapy or combination therapy
Trial: 15517078
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg three times daily for 4 weeks)
Trial: 11781669
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin A (200,000 IU) on admission and placebo daily until discharge
Trial: 11781669
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin A (5,000 IU) daily from admission until discharge
Trial: 11781669
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily from admission until discharge
Trial: 9264493
Drug: Felodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (5 mg BID)
Trial: 31503155
Drug: Nitrofurantoin 100
RxNorm normalized name: nitrofurantoin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin 100 mg daily
Trial: 25346093
Drug: Calcipotriol/betamethasone dipropionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol/betamethasone dipropionate topical gel (once daily for 8 weeks)
Trial: 15253730
Drug: Deferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred treatment (erythropoietin initiated when hemoglobin <9 g/dL)
Trial: 9385487
Drug: Once-daily (QD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily (QD) formulation of loratadine 10 mg and pseudoephedrine sulfate 240 mg
Trial: 8100153
Drug: UDCA 600
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 600 mg/day for 3 months
Trial: 8100153
Drug: Long-term UDCA
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term UDCA treatment (mean 20 months)
Trial: 17907263
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg ST zolpidem
Trial: 14663041
Drug: riluzole 200
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: riluzole 200 mg/day
Trial: 8864970
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment mainly using spinal manipulation
Trial: 1378155
Drug: Carvedilol (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (25-50 mg once daily, starting at 12.5 mg for 2 days)
Trial: 14751571
Drug: GLP-2 injection
RxNorm normalized name: (Gly2)GLP-2
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: GLP-2 injection
Trial: 26993372
Drug: Moderate ibudilast
RxNorm normalized name: ibudilast
DrugBank: Ibudilast (DB05266)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Moderate ibudilast (40 mg)
Trial: 26993372
Drug: High-dose ibudilast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ibudilast (100 mg)
Trial: 23163191
Drug: 7-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent pneumococcal conjugate vaccine (7vPCV) administered at ages 0, 1, and 2 months or at 1, 2, and 3 months
Trial: 8857017
Drug: Cardiac troponin
RxNorm normalized name: Cardiac troponin I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac troponin I levels of at least 0.4 ng/mL
Trial: 8857017
Drug: Cardiac troponin
RxNorm normalized name: Cardiac troponin I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac troponin I levels below 0.4 ng/mL
Trial: 8857017
Drug: Increase of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase of 1 ng/mL in cardiac troponin I level
Trial: 1764383
Drug: Early stage
RxNorm normalized name: SALICYLIC ACID 0.14 mg TOPICAL PATCH [Peace Out Early Stage Acne Dot]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early stage protocol (adjuvant therapy)
Trial: 113810
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 1 week
Trial: 17725246
Drug: Moxonidine, 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine, 0.6 mg/day
Trial: 9153445
Drug: Dextromethorphan (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (mean dose 381 mg/day)
Trial: 24612502
Drug: Metformin (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2000 mg/day) plus letrozole (2.5 mg/day)
Trial: 29654415
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus letrozole (2.5 mg/day)
Trial: 9316528
Drug: Losartan 25
RxNorm normalized name: LOSARTAN 25MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 25 mg/day
Trial: 29092886
Drug: 2RDA (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2RDA (1.6 g protein · kg‐1 · d‐1)
Trial: 19297572
Drug: CMV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV vaccine (recombinant CMV envelope glycoprotein B with MF59 adjuvant)
Trial: 17144474
Drug: Xiaozheng pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaozheng pills
Trial: 29356022
Drug: Optical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optical treatment with corrective lenses based on cycloplegic refraction for amblyopia
Trial: 29356022
Drug: Optical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optical treatment
Trial: 26165528
Drug: Non-rebreather mask
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-rebreather mask (NRB) at 15 L·min⁻¹
Trial: 18182467
Drug: PE +
RxNorm normalized name: Chlorpheniramine Maleate/Phenylephrine Hydrochloride 4 MG-10 MG Oral Tablet [SINUS PE + ALLERGY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PE + F + D (both type I and type II agonists)
Trial: 12855334
Drug: Nerve growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve growth factor (NGF) injection (5 microg in 0.2 ml) into the masseter muscle
Trial: 12855334
Drug: Buffered isotonic
RxNorm normalized name: ISOTON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered isotonic saline injection into the masseter muscle
Trial: 8708517
Drug: Estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol valerate 2 mg/day for 21 days and Norgestrel 0.5 mg/day from day 12 to 21 for the first 8 weeks, followed by placebo for the last 8 weeks
Trial: 6814471
Drug: BHT 933
RxNorm normalized name: BHT
DrugBank: Butylated hydroxytoluene (DB16863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BHT 933 (5 mg)
Trial: 6814471
Drug: BHT 933
RxNorm normalized name: BHT
DrugBank: Butylated hydroxytoluene (DB16863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BHT 933 (10 mg)
Trial: 28542675
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of intravenous acetaminophen (IVAPAP)
Trial: 28542675
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 mL saline infusion)
Trial: 23343675
Drug: Bing sweet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bing sweet cherries (280 g/d) for 28 days
Trial: 20056649
Drug: Calcium (2
RxNorm normalized name: calcium (2ξ)-D-gluco-heptonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (2 g/d)
Trial: 19359985
Drug: Theophylline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (200 to 800 mg daily for 2- to 8-month periods)
Trial: 22475307
Drug: Food associated
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food associated with familiar characters (e.g., sugary or salty snacks)
Trial: 20353747
Drug: Clopidogrel besylate
RxNorm normalized name: Clopidogrel besylate
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel besylate (test formulation)
Trial: 20353747
Drug: Clopidogrel bisulfate
RxNorm normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel bisulfate (reference formulation)
Trial: 19027436
Drug: In vivo
RxNorm normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vivo exposure therapy
Trial: 23796315
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality exposure therapy
Trial: 12520629
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate (4.5 g) administered after an overnight fast
Trial: 12520629
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate (4.5 g) administered after a high-fat meal
Trial: 11574436
Drug: Hypoglycemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemia (blood glucose 2.59 [0.19] mmol/l)
Trial: 3662586
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) 200 micrograms twice daily
Trial: 21612468
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (1000 mg) with prednisone (5 mg twice daily)
Trial: 21612468
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with prednisone (5 mg twice daily)
Trial: 19218816
Drug: Omalizumab administered
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab administered subcutaneously every 2 or 4 weeks based on serum IgE level and body weight.
Trial: 9770887
Drug: Anti Hp
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti Hp IgG antibodies
Trial: 1251775
Drug: Streptokinase and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase and heparin
Trial: 28235531
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (1mg/kg) of propofol and normoventilation (ETCO2 of 40‐45mmHg) (group P/N)
Trial: 28235531
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose (0.5mg/kg) of propofol with divided remifentanil injections and normoventilation (group RP/N)
Trial: 19563190
Drug: Fire-needle therapy
RxNorm normalized name: Fire Out
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fire-needle therapy
Trial: 16641466
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of ermB, ermTR, and mefA/E antibiotic resistance genes
Trial: 11380515
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E therapy
Trial: 7521724
Drug: Hepatic resection
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic resection after IL-2 therapy
Trial: 16567830
Drug: Pioglitazone 45
RxNorm normalized name: pioglitazone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 45 mg/day for 24 weeks
Trial: 11570313
Drug: Monthly combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly combination injectable contraceptive (estradiol cypionate and medroxyprogesterone acetate)
Trial: 3045028
Drug: Potassium chloride
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potassium chloride 1 g twice/day
Trial: 27009057
Drug: Tailored behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored behavioural medicine treatment
Trial: 22999398
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg enantiomeric excess hyperbaric levobupivacaine
Trial: 2611360
Drug: Flurbiprofen with
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen with Maalox (antacid)
Trial: 2611360
Drug: Flurbiprofen every
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen every 12 h from Day 3 to Day 8 with Maalox (antacid)
Trial: 6740281
Drug: Duck embryo
RxNorm normalized name: Duck
DrugBank: Duck (DB10610)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duck embryo rabies vaccine (DEV)
Trial: 21415046
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) with fluoxetine if indicated, 20 sessions over 18 weeks